Allopurinol hypersensitivity syndrome (AHS) is a severe and sometimes
Allopurinol is the most commonly prescribed urate-lowering therapy for the management
Allopurinol hypersensitivity syndrome (AHS) is an infrequent but life-threatening adverse
Allopurinol is the first-line urate-lowering therapy in most people with gout and overall is well-tolerated
Patients receiving allopurinol are at risk of developing the allopurinol hypersensitivity syndrome, an immunologic reaction to the drug, characterized by multiple abnormalities such as fever, rash, decreased renal function, hepatocellular injury, leukocytosis, and eosinophilia
Although AHS is rare, the number of patients with gout requiring allopurinol is high, and there are sufficient overall cases of AHS to warrant consideration of preventive measures
Allopurinol hypersensitivity syndrome (AHS) is a rare but potentially fatal adverse event
Symptoms generally begin 2–6 weeks after the initiation of therapy
Allopurinol is generally well tolerated
Certainly, you should not normally stop taking allopurinol once started except for clearly defined medical situations
Allopurinol can build up in the body in people with liver disease or kidney disease, so dose adjustments or extra monitoring may be required
Treatment of these syndromes is based on immediate removal of the offending agent, supportive Even lower initial allopurinol doses (e
Background: Allopurinol is the primary therapy for the management of chronic gout
Approximately 2% of patients develop a mild rash 64 and up to 5% of patients stop allopurinol due to adverse events